EGFR and non-small cell lung carcinoma: As reported in FLAURA trial, osimertinib can significantly prolong PFS and OS of patients with treatment-naïve EGFR-mutant advanced NSCLC and reduce the risk of central nervous system (CNS) metastasis, compared with first-generation EGFR-TKIs (Ramalingam et al., 2020).